The drug of choice for the initial treatment of "decoppering" in Wilson's disease, an inherited disorder of copper metabolism, is the chelating agent D-penicillamine. In the case of harmful side-effects an alternative drug is triethylenetetramine dihydrocholoride (trien or trientine). Using the 24-h-urine excretion of copper and the oral copper loading test with copper-64, a double function for trien was found: trien increases the urine copper excretion and decreases the intestinal copper absorption respectively.
No takes yet. Share an insight, caveat, or question.
Siegemund et al. (1991) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: